CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10036|
|Strength||1, 2, 3, 4 mg capsules|
|Funding Request||In combination with low-dose dexamethasone for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||Yes|
|NOC Date||January 20, 2014|
|Submission Date||January 13, 2014|
|Submission Deemed Complete||January 20, 2014|
|Submission Type||New Drug|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||January 27, 2014|
|Check-point meeting||March 18, 2014|
|pERC Meeting||May 15, 2014|
|Initial Recommendation Issued||May 30, 2014|
|Feedback Deadline ‡||June 13, 2014|
|pERC Reconsideration Meeting||July 17, 2014|
|Final Recommendation Issued||July 31, 2014|
|Notification to Implement Issued||August 18, 2014|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.